Disc Medicine's (IRON) Buy Rating Reaffirmed at HC Wainwright

Disc Medicine (NASDAQ:IRON - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They presently have a $70.00 target price on the stock. HC Wainwright's price objective points to a potential upside of 51.55% from the stock's previous close.

Several other equities research analysts have also recently weighed in on IRON. Wells Fargo & Company began coverage on shares of Disc Medicine in a research report on Thursday, August 22nd. They set an "overweight" rating and a $75.00 price objective for the company. Scotiabank initiated coverage on shares of Disc Medicine in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $62.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a research report on Tuesday, October 15th. Wedbush restated an "outperform" rating and issued a $57.00 price target on shares of Disc Medicine in a report on Friday, August 9th. Finally, Jefferies Financial Group started coverage on shares of Disc Medicine in a report on Wednesday, October 23rd. They set a "buy" rating and a $89.00 price objective on the stock. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $66.40.

Disc Medicine Price Performance

IRON stock traded up $0.18 during midday trading on Monday, reaching $46.19. 298,488 shares of the stock were exchanged, compared to its average volume of 346,274. The stock has a market capitalization of $1.14 billion, a PE ratio of -13.61 and a beta of 0.59. Disc Medicine has a 52 week low of $25.60 and a 52 week high of $77.60. The company has a fifty day moving average price of $48.92 and a 200 day moving average price of $42.21.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.11) by $0.08. As a group, analysts anticipate that Disc Medicine will post -4.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds have recently modified their holdings of IRON. Amalgamated Bank grew its holdings in shares of Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company's stock valued at $26,000 after acquiring an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock valued at $54,000 after purchasing an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine during the 2nd quarter valued at $129,000. SG Americas Securities LLC grew its position in Disc Medicine by 44.2% during the second quarter. SG Americas Securities LLC now owns 4,071 shares of the company's stock valued at $183,000 after buying an additional 1,247 shares during the period. Finally, ProShare Advisors LLC purchased a new stake in Disc Medicine during the first quarter worth about $211,000. Institutional investors own 83.70% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.